Medical Xpress August 2, 2024
Mantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatment appears to be successful, the cancer often returns and is difficult to cure.
A new therapy has been approved by the U.S. Food and Drug Administration (FDA) for these most challenging cases: lisocabtagene maraleucel, or Breyanzi. The approval was based on results from a clinical trial led by MSK hematologist oncologist Lia Palomba, MD.
“We now have a good option for a type of lymphoma that has been very difficult to treat when other therapies fail,” Dr. Palomba says. “This is urgently needed because the disease grows more resistant every time it comes back.”
Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T...
Today's Sponsors
Today's Sponsor